(4-氟联苯-4-基)-甲醇 | 147497-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氟联苯-4-基)-甲醇
• 中文别名: 4-(4-氟苯基)苄醇
• 英文名称: (4'-fluoro-[1,1'-biphenyl]-4-yl)methanol
• 英文别名: (4′-fluoro-[1,1′-biphenyl]-4-yl)methanol；(4'-Fluoro-biphenyl-4-yl)-methanol；[4-(4-Fluorophenyl)phenyl]methanol
• CAS: 147497-56-1
• 化学式: C₁₃H₁₁FO
• 分子量: 202.228
• InChiKey: ZSWIVXLMMVNSCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Fluorophenyl)benzyl alcohol
Synonyms: (4’-Fluorobiphenyl-4-yl)-methanol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Fluorophenyl)benzyl alcohol
CAS number: 147497-56-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H11FO
Molecular weight: 202.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-氟联苯-4-基)-甲醇 在 三溴化磷 作用下， 以 二氯甲烷 为溶剂， 生成 4-(溴甲基)-4-氟-1,1-联苯
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION

  摘要：

  披露于此的是公式I的化合物： 或其盐以及包含公式I化合物或其药用可接受盐的组成。还披露了用于治疗或预防动物细菌感染的方法，包括向动物单独或与细菌外排泵抑制剂联合给药公式I化合物或其药用可接受盐。

  公开号：

  US20190031624A1
• 作为产物：
  描述：

  methyl 4'-fluoro-[1,1'-biphenyl]-4-carboxylate 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 (4-氟联苯-4-基)-甲醇
  参考文献：
  名称：

  Isoquinolyl substituted hydroxylamine derivatives

  摘要：

  该化合物的分子式为##STR1##其中R代表氢、较低的烷基、芳基、双芳基、C.sub.3 -C.sub.7 -环烷基、芳基-较低的烷基、芳基-较低的烯基、芳基-较低的炔基、芳氧基-较低的烷基、芳硫基-较低的烷基；C.sub.3 -C.sub.7 -环烷基-较低的烷基、双芳基-较低的烷基、芳基-C.sub.3 -C.sub.7 -环烷基、芳基-C.sub.3 -C.sub.7 -环烷基-较低的烷基或芳氧基-芳基-较低的烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1 -C.sub.3 -烷基或乙烯基，每个未取代或被较低的烷基取代；Y代表SO.sub.2或CO；A代表O、S或直接键；B代表较低的烷基；或者B代表较低的烯基，前提是A代表直接键；X代表氧或硫；R.sub.1代表氢、酰基、较低的烷氧羰基、氨基羰基、单取代或双较低的烷基氨基羰基、较低的烯基氨基羰基、较低的炔基氨基羰基、碳环芳基或杂环芳基-较低的烷基氨基羰基、碳环芳基或杂环芳基氨基羰基、C.sub.3 -C.sub.7 -环烷基氨基羰基或C.sub.3 -C.sub.7 -环烷基-较低的烷基氨基羰基；R.sub.2代表较低的烷基、较低的烷氧羰基-较低的烷基、C.sub.3 -C.sub.7 -环烷基、碳环芳基或杂环芳基、碳环芳基或杂环芳基-较低的烷基、C.sub.3 -C.sub.7 -环烷基-较低的烷基、氨基、单或双较低的烷基氨基、较低的烯基氨基、较低的炔基氨基、碳环芳基或杂环芳基-较低的烷基氨基、碳环芳基或杂环芳基氨基、C.sub.3 -C.sub.7 -环烷基氨基、C.sub.3 -C.sub.7 -环烷基-较低的烷基氨基或较低的烷氧羰基-较低的烷基氨基；R.sub.3和R.sub.4独立地代表氢或较低的烷基；R.sub.a代表氢、较低的烷基、卤素、三氟甲基或较低的烷氧基；以及它们的药学接受的盐；描述了它们的制备和用作脂氧酶抑制剂。

  公开号：

  US05260316A1

文献信息

• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2019104011A1

  公开（公告）日：2019-05-31

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本发明涉及化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与鞘氨醇半乳糖基转移酶（CGT）相关疾病或失调的方法，例如，例如，溶酶体贮积病。溶酶体贮积病的例子包括，例如，克拉伯病和异染性脑白质营养不良。
• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Lantheus Medical Imaging, Inc.

  公开号：US20150196672A1

  公开（公告）日：2015-07-16

  The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

  本发明提供了具有成像基团的化合物，用于对受试者进行成像。本发明还涉及用于合成和使用成像试剂或其前体的系统、组合物和方法。成像试剂前体可以使用本文所述的方法转化为成像试剂。在某些情况下，组合物或多种成像试剂富集于 18 F。在某些情况下，成像试剂可用于成像受试者的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。
• Compounds that modulate PPAR activity and methods for their preparation
  申请人：——

  公开号：US20030225158A1

  公开（公告）日：2003-12-04

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  该发明揭示了可以改变PPAR活性的化合物。该发明还揭示了这些化合物的药用可接受盐、含有这些化合物或其盐的药用可接受组合物，以及将它们用作治疗或预防哺乳动物的失脂血症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉粥样硬化、高甘油三酯血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• [EN] 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] PYRIDINES 2,6-DISUBSTITUÉES COMME ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009071504A1

  公开（公告）日：2009-06-11

  Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

  公开的是式（I）的化合物，其中R1和R2分别选自氢、卤素、CF3、C1-4烷基和烯丙基；Y代表（II）、（III）、（IV）或（V），其中R3代表CF3或C1-4烷基；而R3a代表CF3或C1-4烷基。
• Importance of monodentate mono-ligand designs in developing N-stabilized Pd catalysts for efficient ambient temperature C C coupling: Donor strengths and steric features
  作者：Abiodun Omokehinde Eseola、Helmar Görls、Winfried Plass

  DOI：10.1016/j.mcat.2019.110398

  日期：2019.8

  catalyst loading, 45 °C and within 15 min. On the other hand, the complexes with trans-bis-ligand coordination were inactive at ambient temperatures. Therefore, it was concluded that coordinative saturation, which results from implementing two or more ligand equivalents or use of polydentate ligands on palladium, should be strongly discouraged. Such saturation necessitates the undesirable and avoidable high

  不友好的温度曲线和碳偶联催化的成本，这对合成有机化学家和工业适用性均构成挑战，促使我们设计新的单齿N-供体作为支撑配体，目的是构建分子上与碳原子接近的环境温度预催化剂。假设的有效形式。因此，一系列的空间变化的单齿N-供体咪唑（的1 - 7）和恶唑（8 - 9）已被合成和它们的N-供体强度，将其估计为的pK一个S，被系统地从0.9通过变化至8.5取代基变化。十一种目标单配体络合物（1 -PdCl 2 MeCN –9 -PdCl 2的MeCN，6 -PdCl 2 PHCN和7 -PdCl 2 PHCN）和6个反式-双-配体复合物（1 2 -PdCl 2，2 2 -PdCl 2，3 2 -PdCl 2，6 2 -PdCl 2，分离出1 2 -Pd（OAc）2和2 2 -Pd（OAc）2）并与PdI 2（PPh 3）2一起进行催化研究。。通过原位“ Pd（II）盐+配体”方法和使用预催化剂进行的偶